Encouraging data on IPH 1101 with final results from phase I clinical trial in solid tumours

Innate pharma presents encouraging data on its immunomodulatory product candidate IPH 1101 with final results from phase I clinical trial in solid tumours (Trial D004-101).

PR in english 135.47 KB
CP en français 122.33 KB